Two new EliA IgG tests for detecting anti-Thyroglobulin (anti-TG) and anti-Thyroid Peroxidase (anti-TPO) autoantibodies in serum or plasma have received FDA clearance and are performed on the fully-automated Phadia 250/2500/5000 Laboratory Systems. Thyroid autoimmunity comprises a number of distinct but pathogenically related autoimmune disorders of the thyroid gland, such as Graves’ disease or Hashimoto’s thyroiditis. Among other things, these diseases are characterized by the presence of autoantibodies, such as anti-Thyroid Simulating Hormone (TSH) receptor, anti-thyroglobulin (TG) or anti-thyroid peroxidase (TPO). More than 98 percent of Hashimoto’s thyroiditis patients have autoantibodies directed to TG or TPO or both. EliA anti-TG and anti-TPO tests quantitatively measure a patient’s autoantibodies to thyroglobulin or thyroid peroxidase, providing information that helps clinicians in the diagnosis of autoimmune thyroid diseases. These new EliA tests, formerly offered as ImmunoCAP tests, provide higher sensitivity with similar or higher specificity. Optimized sensitivity and specificity minimizes false negative or positive results, and maximizes detection of patients with serious disease.